NCIt definition : An antibody-drug conjugate (ADC) composed of trastuzumab, a humanized immunoglobulin
G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA)
human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2), conjugated to the microtubule-disrupting
cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity.
Upon administration of trastuzumab vedotin, the trastuzumab moiety targets and binds
to HER2 on the surface of tumor cells. Following internalization, MMAE targets and
binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase
cell cycle arrest and apoptosis in HER2-expressing tumor cells. HER2, a tyrosine kinase
receptor, is overexpressed by many cancer cell types.;
UNII : RB3U3A1S27;
CAS number : 2136633-23-1; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2136633-23-1
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;